BackChromadex Overview

Chromadex Total Revenue

Latest total revenue for CDXC: $57M, below the Healthcare sector average of $12T.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$27.19M

As of Sep 2026

Annual Revenue (TTM)

$56.98M
↑ 95.63% YoY

Trailing 12 months ending Sep 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Chromadex (CDXC) FAQ

The latest total revenue for CDXC is $57M as of September 2026. That compares with $29M in the prior-year period — up 95.6% year over year. That is below the Healthcare sector average of $12T. Investors often review this figure alongside Chromadex's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDXC's total revenue moved from $29M to $57M — a 95.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chromadex's operating scale or balance-sheet position.

Against Healthcare companies, CDXC currently prints $57M for total revenue, while the sector average sits near $12T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Chromadex's growth, margins, and balance sheet.

A total revenue figure of $57M for CDXC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $12T. Explore the charts below for those layers of context.

After noting CDXC's total revenue ($57M), review year-over-year change from $29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.